<DOC>
	<DOCNO>NCT00002757</DOCNO>
	<brief_summary>RATIONALE : Less intensive therapy may attain result intensive therapy child non-Hodgkin 's lymphoma . PURPOSE : Randomized phase III trial study effectiveness less intensive therapy child non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>TITLE : Less Intensive Therapy Children With Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Confirm previously find excellent survival low-risk patient ( Group A ) B-cell lymphoma/leukemia treat LMB 89 regimen . - Verify good event-free survival retain intermediate-risk patient ( Group B ) dose cyclophosphamide ( CTX ) number CTX-containing regimen reduce . - Verify good event-free survival retain high-risk patient ( Group C ) despite reduction dos consolidation therapy reduce number maintenance course , , patient CNS involvement , additional intravenous intrathecal methotrexate place cranial irradiation . - Monitor survival event-free survival patient register prior first chemotherapy course . - Compare survival event-free survival Group C patient CNS involvement result treat LMB 89 study . - Compare event-free survival survival patient large cell Burkitt 's Burkitt's-like lymphoma . - Monitor long-term toxicity patient treat study , include fertility , cardiotoxicity , secondary malignancy . - Characterize biology childhood small non-cleaved cell lymphoma respect drug resistance ( i.e. , topoisomerase II MDR activity ) , viral association ( i.e. , Epstein-Barr virus , human immunodeficiency virus , human herpesvirus 6 ) , specific breakpoint translocation ( i.e. , IgH C-myc ) per companion study CCG-B944 . - Characterize biology childhood mature B-cell lymphoma per UKCCSG study . OUTLINE : This randomize study . Patients stratify accord participate group ( UKCCSG vs SFOP v CCG ) , histology ( large cell v small non-cleaved cell ) , risk group ( Group A v Group B v Group C ) . Stage III Group B patient stratify accord Murphy stage ( stage I/II v III v III/IV ) LDH ( less twice normal vs twice normal high ) . Group C patient stratify base presence CNS disease ( yes v ) . Patients resect stage I resect abdominal-only stage II disease treat Group A Regimen . Patients unresected stage I/II , stage III , CNS-negative stage IV disease few 25 % blast bone marrow treat Group B Regimen . Patients 25 % blast bone marrow CNS involvement ( i.e. , L3 blast CSF , cranial nerve palsy , clinical spinal cord compression , isolated intracerebral mass , parameningeal cranial spinal extension ) treat Group C Regimen . The following acronym use : - ARA-C Cytarabine , NSC-63878 - CF Leucovorin calcium , NSC-3590 - COP CTX/VCR/PRED ( PRDL ) - COPAD CTX/VCR/PRED ( PRDL ) /DOX - COPADM CTX/VCR/PRED ( PRDL ) /DOX/MTX - CTX Cyclophosphamide , NSC-26271 - CYM ARA- C/MTX - CYVE ARA-C/VP-16 - DOX Doxorubicin , NSC-123127 - G-CSF Granulocyte Colony-Stimulating Factor ( Amgen ) , NSC-614629 - HC Hydrocortisone , NSC-10483 - HD High Dose - MTX Methotrexate , NSC-740 - PRDL Prednisolone , NSC-9900 - PRED Prednisone , NSC-10023 - TIT Triple Intrathecal Chemotherapy ( IT MTX/IT HC/IT ARA-C ) - VCR Vincristine , NSC-67574 - VP-16 Etoposide , NSC-141540 Group A Regimen ( Low-Risk Patients ) - Induction : Patients receive COPAD : VCR IV day 1 6 , oral PRED ( IV ) twice daily day 1-5 , taper 3 day , CTX IV 15 minute every 12 hour day 1-3 , DOX IV 6 hour day 1 start first CTX dose . G-CSF SC administer hematopoietic recovery begin day 7 . Patients receive second course begin day 21 . Group B Regimen ( Intermediate-Risk Patients ) - Induction 1 : Patients receive CTX IV 15 minute day 1 , VCR IV day 1 , oral PRED day 1-7 , MTX IT HC IT day 1 . Patients respond disease proceed COPADM . Patients response proceed treatment arm I Group C Regimen . - COPADM 1 : Patients receive VCR IV day 8 , oral PRED twice daily day 8-12 , taper 3 day , MTX IV 3 hour day 8 , oral CF every 6 hour 12 dos begin 24 hour start MTX , CTX IV 15 minute every 12 hour day 9-11 , DOX IV 6 hour day 9 begin first CTX dose . G-CSF administer Group A Regimen . MTX IT HC IT give day 9 13 . - Group B patient randomize 1 4 treatment follow recovery disease assessment : Arm I : - Induction 2 ( begin sooner 16 day start COPADM 1 ) : Patients receive COPADM 2 accord schedule COPADM 1 Induction 1 except CTX increase . G-CSF administer Group A Regimen . Patients receive MTX IT HC IT day 2 6 . - Consolidation : Patients receive CYM : MTX IV 3 hour day 1 , oral CF every 6 hour maximum 12 dos begin 24 hour start MTX , ARA-C IV 24 hour day 2-6 . Patients receive TIT : MTX IT day 2 , HC IT day 2 7 , ARA-C IT day 7 . - Response assess upon recovery resection residual mass . If histology negative patient proceed second course CYM . If histology positive patient proceed CYVE arm I Group C Regimen . - Maintenance : Patients receive COPADM 3 COPADM 1 Induction 1 , except CTX IV administer 30 minute day 2 3 , MTX IT HC IT administer day 2 . Arm II : - Induction 2 : Patients receive COPADM 2 arm I Group B Regimen . G-CSF administer Group A Regimen . MTX IT HC IT administer Induction 1 . - Consolidation : Patients receive CYM , TIT , response assessment arm I Group B Regimen . - Maintenance : Patients receive maintenance therapy . Arm III : - Induction 2 : Patients receive COPADM 2 COPADM 1 Induction 1 . G-CSF administer Group A Regimen . Patients receive MTX IT HC IT Induction 1 . - Consolidation : Patients receive CYM , TIT , response assessment arm I Group B Regimen . - Maintenance : Patients receive COPADM 3 arm I Group B Regimen . Patients receive MTX IT HC IT day 2 . Arm IV : - Induction 2 : Patients receive COPADM 2 COPADM 1 Induction 1 . G-CSF administer Group A Regimen . Patients receive MTX IT HC IT Induction 1 . - Consolidation : Patients receive CYM , TIT , response assessment arm I Group B Regimen . - Maintenance : Patients receive maintenance therapy . Group C Regimen ( High-Risk Patients ) - Induction : Patients receive COP Induction 1 Group B Regimen , TIT day 1 , 3 , 5 , oral CF every 12 hour day 2 4 . Tumor response evaluate day 7 treatment decision make Induction 1 Group B Regimen . Patients receive COPADM 1 COPADM 1 Induction 1 Group B Regimen except HD MTX IV give 4 hour day 1 . G-CSF administer Group A Regimen . TIT give day 2 , 4 , 6 . Patients receive COPADM 2 COPADM 2 arm I Group B Regimen , Induction 2 except HD MTX IV give 4 hour day 1 . G-CSF administer Group A Regimen . Patients receive TIT day 2 , 4 , 6 . - Patients randomize 1 2 treatment arm upon recovery disease assessment : Arm I : - Consolidation : Patients receive CYVE : ARA-C IV day 1-5 , VP-16 IV 2 hour day 2-5 . G-CSF administer Group A Regimen . For patient CNS disease : MTX IT HC IT day 1 , 6 hour prior initiation ARA-C , HD MTX IV 4 hour , day 18 , oral CF every 6 hour maximum 12 dos , begin 24 hour start MTX , TIT prior begin CF . - Response assess upon recovery resection residual mass . Patients complete response receive second course CYVE ( HD MTX/CF ) , begin 1 week HD MTX . - Maintenance ( 28 day course ) : - Course 1 : Patients receive COPADM arm I Maintenance Group B Regimen , except HD MTX administer Group C Induction , TIT give day 2 replace MTX IT HC . - Course 2 : Patients receive CYVE : ARA-C IV every 12 hour day 1-5 , VP-16 IV 90 minute day 1-3 . - Course 3 : Patients receive COPAD Group B Induction 1 , except CTX IV administer 30 minute day 1 2 . - Course 4 : Patients receive treatment identical Course 2 . Arm II : - Consolidation : Patients receive Mini-CYVE : ARA-C IV day 1-5 , VP-16 IV 1 hour day 2-5 . G-CSF administer Group A Regimen . For patient CNS disease : MTX IT HC IT arm I Group C Regimen , HD MTX , CF , TIT arm I Group C Regimen . - Response assess upon recovery resection residual mass . Patients complete response receive second course CYVE ( HD MTX CF ) begin 1 week HD MTX . - Maintenance : Patients receive COPADM TIT arm I Group C Regimen Course 1 1 course . Patients follow every 3 month 6 month , every 6 month 2.5 year , annually thereafter . PROJECTED ACCRUAL : A total 900 patient accrue study within 5 year . Yearly accrual expect 20 Group A patient , 115 Group B patient , 45 Group C patient .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : One follow diagnosis : Newly diagnose Bcell nonHodgkin 's lymphoma Revised EuropeanAmerican Lymphoma ( REAL ) categories II 9 , 10 , 11 , i.e . : Diffuse large cell Burkitt 's Highgrade Bcell , Burkitt'slike L3 leukemia great 5 % blast bone marrow No anaplastic large cell Ki1positive lymphoma Immunophenotype Murphy stage require prior randomization PATIENT CHARACTERISTICS : Age : Over 6 month 21 year Maximum age 18 year France United Kingdom Other : No congenital immunodeficiency No prior organ transplantation No prior malignancy Not HIV positive Available least 36 month followup PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Steroids initiate 72 hour prior entry allow Bone marrow cerebrospinal fluid examination require prior steroid Radiotherapy : Emergency radiotherapy initiate 72 hour prior entry allow Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>childhood Burkitt lymphoma</keyword>
	<keyword>untreated childhood acute lymphoblastic leukemia</keyword>
	<keyword>L3 childhood acute lymphoblastic leukemia</keyword>
	<keyword>stage I childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage I childhood large cell lymphoma</keyword>
	<keyword>stage II childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage II childhood large cell lymphoma</keyword>
	<keyword>stage III childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage III childhood large cell lymphoma</keyword>
	<keyword>stage IV childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage IV childhood large cell lymphoma</keyword>
</DOC>